New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Neil Gregory Almstead net worth and biography

Neil Almstead Biography and Net Worth

Insider of PTC Therapeutics

Neil Almstead, Ph.D., has served in several executive positions since joining PTC in 2000 and currently oversees manufacturing and supply chain for the small-molecule and gene-therapy programs. Previously, he was a project manager at Procter & Gamble. Neil has co-authored more than 75 publications and patents in the area of genetic disorders, oncology, and inflammatory diseases. Neil received a B.S. from Clarkson University and a Ph.D. in organic chemistry from the University of Illinois at Urbana-Champaign.

What is Neil Gregory Almstead's net worth?: The estimated net worth of Neil Gregory Almstead is at least $2.57 million as of January 30th, 2024. Dr. Almstead owns 61,202 shares of PTC Therapeutics stock worth more than $2,568,036 as of November 20th. This net worth estimate does not reflect any other investments that Dr. Almstead may own. Additionally, Dr. Almstead receives a salary of $829,970.00 as Insider at PTC Therapeutics. Learn More about Neil Gregory Almstead's net worth.
How old is Neil Gregory Almstead?: Dr. Almstead is currently 57 years old. There are 7 older executives and no younger executives at PTC Therapeutics. The oldest executive at PTC Therapeutics is Dr. Allan Steven Jacobson Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director, who is 78 years old. Learn More on Neil Gregory Almstead's age.
What is Neil Gregory Almstead's salary?: As the Insider of PTC Therapeutics, Inc., Dr. Almstead earns $829,970.00 per year. There are 3 executives that earn more than Dr. Almstead. The highest earning executive at PTC Therapeutics is Dr. Stuart W. Peltz Ph.D., Co-Founder, Senior Consultant & Member of Scientific Advisory Board, who commands a salary of $1,540,000.00 per year. Learn More on Neil Gregory Almstead's salary.
How do I contact Neil Gregory Almstead?: The corporate mailing address for Dr. Almstead and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Neil Gregory Almstead's contact information.
Has Neil Gregory Almstead been buying or selling shares of PTC Therapeutics?: Neil Gregory Almstead has not been actively trading shares of PTC Therapeutics during the past quarter. Most recently, Neil Gregory Almstead sold 618 shares of the business's stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $27.25, for a transaction totalling $16,840.50. Following the completion of the sale, the insider now directly owns 61,202 shares of the company's stock, valued at $1,667,754.50. Learn More on Neil Gregory Almstead's trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, PTC Therapeutics insiders bought shares 1 times. They purchased a total of 7,700 shares worth more than $198,737.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 56,906 shares worth more than $1,787,917.16. The most recent insider tranaction occured on July, 16th when CFO Pierre Gravier sold 2,269 shares worth more than $77,191.38. Insiders at PTC Therapeutics own 5.5% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 7/16/2024.

Neil Gregory Almstead Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/30/2024	Sell	618	$27.25	$16,840.50	61,202
1/11/2023	Sell	383	$44.36	$16,989.88	64,579
1/9/2023	Sell	716	$41.66	$29,828.56	65,435
1/7/2022	Sell	756	$38.52	$29,121.12
1/4/2022	Sell	64	$41.16	$2,634.24
2/1/2021	Sell	973	$56.96	$55,422.08	35,814
1/25/2021	Sell	541	$63.15	$34,164.15	36,849
1/23/2020	Sell	46	$53.25	$2,449.50
1/6/2020	Sell	507	$48.17	$24,422.19	16,889
6/19/2018	Sell	20,000	$48.31	$966,200.00	37,154
1/4/2018	Sell	77	$17.67	$1,360.59
1/5/2017	Sell	78	$11.82	$921.96
4/15/2015	Sell	9,511	$68.65	$652,930.15
3/10/2015	Sell	79	$70.71	$5,586.09
1/21/2015	Sell	26,096	$60.26	$1,572,544.96
3/19/2014	Sell	10,859	$31.91	$346,510.69	29,881

Neil Gregory Almstead Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $41.96

$38.26

$42.79

50 Day Range

MA: $38.72

$32.27

$44.87

2 Week Range

Now: $41.96

$20.75

$46.98

Volume

722,545 shs

Average Volume

766,640 shs

Market Capitalization

$3.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

From Darwin | Ad

👉 Click here to access your FREE report now!

Neil Almstead Biography and Net Worth

What is Neil Gregory Almstead's net worth?

How old is Neil Gregory Almstead?

What is Neil Gregory Almstead's salary?

How do I contact Neil Gregory Almstead?

Has Neil Gregory Almstead been buying or selling shares of PTC Therapeutics?

Who are PTC Therapeutics' active insiders?

Are insiders buying or selling shares of PTC Therapeutics?